To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.

An Open-Label Extension Safety and Efficacy Study of Pregabalin in Patients With Postherpetic Neuralgia

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00150436

Enrollment

276

Registered

2005-09-08

Start date

2002-02-28

Completion date

2005-07-31

Last updated

2006-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuralgia

Brief summary

To evaluate long-term safety and efficacy of pregabalin in patients with postherpetic neuralgia.

Interventions

DRUGPregabalin

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Must have met the inclusion criteria for preceding double-blind BID study in postherpetic neuralgia * Must have received pregabalin/placebo under double-blind conditions for a minimum of 3 weeks.

Exclusion criteria

* Patients cannot participate if they experienced a serious adverse event during preceding double-blind BID study which was determined to be related to the study medication.

Design outcomes

Primary

Measure	Time frame
Safety Efficacy	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026